| Title |
Relaxin, a pleiotropic vasodilator for the treatment of heart failure
|
|---|---|
| Published in |
Heart Failure Reviews, December 2008
|
| DOI | 10.1007/s10741-008-9129-3 |
| Pubmed ID | |
| Authors |
Sam L. Teichman, Elaine Unemori, Thomas Dschietzig, Kirk Conrad, Adriaan A. Voors, John R. Teerlink, G. Michael Felker, Marco Metra, Gad Cotter |
| Abstract |
Relaxin is a naturally occurring peptide hormone that plays a central role in the hemodynamic and renovascular adaptive changes that occur during pregnancy. Triggering similar changes could potentially be beneficial in the treatment of patients with heart failure. The effects of relaxin include the production of nitric oxide, inhibition of endothelin, inhibition of angiotensin II, production of VEGF, and production of matrix metalloproteinases. These effects lead to systemic and renal vasodilation, increased arterial compliance, and other vascular changes. The recognition of this has led to the study of relaxin for the treatment of heart failure. An initial pilot study has shown favorable hemodynamic effects in patients with heart failure, including reduction in ventricular filling pressures and increased cardiac output. The ongoing RELAX-AHF clinical program is designed to evaluate the effects of relaxin on the symptoms and outcomes in a large group of patients admitted to hospital for acute heart failure. This review will summarize both the biology of relaxin and the data supporting its potential efficacy in human heart failure. |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 3% |
| Germany | 2 | 3% |
| Australia | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 58 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 20% |
| Student > Master | 7 | 11% |
| Student > Ph. D. Student | 6 | 9% |
| Student > Doctoral Student | 5 | 8% |
| Professor | 5 | 8% |
| Other | 20 | 31% |
| Unknown | 8 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 41% |
| Agricultural and Biological Sciences | 17 | 27% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Chemistry | 3 | 5% |
| Other | 2 | 3% |
| Unknown | 9 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2017.
All research outputs
#4,697,128
of 22,792,160 outputs
Outputs from Heart Failure Reviews
#130
of 667 outputs
Outputs of similar age
#26,179
of 167,949 outputs
Outputs of similar age from Heart Failure Reviews
#1
of 9 outputs
Altmetric has tracked 22,792,160 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 667 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 167,949 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them